U.S. markets open in 5 hours 1 minute

Radius Health, Inc. (RDUS)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
12.10-0.04 (-0.33%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Slow Stochastic

Slow Stochastic

Previous Close12.14
Bid0.00 x 1800
Ask14.93 x 900
Day's Range12.01 - 12.39
52 Week Range10.32 - 29.97
Avg. Volume608,550
Market Cap562.315M
Beta (5Y Monthly)1.12
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Radius Health (RDUS) Q2 2020 Earnings Call Transcript
    Motley Fool

    Radius Health (RDUS) Q2 2020 Earnings Call Transcript

    Ladies and gentlemen, thank you for standing by, and welcome to the second-quarter 2020 Radius Health earnings conference call. Before we begin, I'd like to remind you with our safe harbor slide that will have some forward-looking statements and include non-GAAP financial measures in our presentation today.

  • Radius Health (RDUS) Reports Q2 Loss, Tops Revenue Estimates

    Radius Health (RDUS) Reports Q2 Loss, Tops Revenue Estimates

    Radius Health (RDUS) delivered earnings and revenue surprises of -15.85% and 3.48%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

  • Benzinga

    Radius Health: Q2 Earnings Insights

    Shares of Radius Health (NASDAQ:RDUS) rose 1.4% in pre-market trading after the company reported Q2 results.Quarterly Results Earnings per share fell 21.82% year over year to ($0.67), which beat the estimate of ($0.74).Revenue of $50,113,000 up by 22.10% from the same period last year, which beat the estimate of $48,400,000.Guidance Radius Health hasn't issued any earnings guidance for the time being.Radius Health hasn't issued any revenue guidance for the time being.How To Listen To The Conference Call Date: Aug 10, 2020View more earnings on RDUSTime: 08:30 AMET Webcast URL: https://edge.media-server.com/mmc/p/whbw94tnRecent Stock Performance 52-week high: $29.9752-week low: $10.32Price action over last quarter: down 17.57%Company Description Radius Health Inc is an integrated biopharmaceutical company. It develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company's product, TYMLOS, is for the treatment of postmenopausal women with osteoporosis at high risk for fracture defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. The product pipeline of the company includes Abaloparatide-patch for the treatment of postmenopausal women with osteoporosis, Elacestrant, and RAD140. It primarily operates the business in the United States of America and generates key revenue from the sales of TYMLOS.See more from Benzinga * Earnings Scheduled For August 10, 2020 * Benzinga's Top Upgrades, Downgrades For July 8, 2020 * 20 Healthcare Stocks Moving In Wednesday's Pre-Market Session(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.